Navigation Links
Obesity Society Disappointed by FDA Delay on Approval of Obesity Drug
Date:2/2/2011

SILVER SPRING, Md., Feb. 2, 2011 /PRNewswire-USNewswire/ -- In its latest blow to obesity medication development efforts, the US Food and Drug Administration (FDA) yesterday notified Orexigen Therapeutics that it would need to conduct an extremely large-scale study of the long-term cardiovascular effects of its drug, Contrave, before approval could be considered.  The economics of such a trial make it extremely unlikely that it can be done; effectively ending hopes for approval, despite the earlier recommendation of the FDA's own advisory panel to approve the drug for use prior to a study.

This makes the third obesity medication that the FDA has disallowed in less than 12 months.  The agency has not approved an obesity drug since 1999, and, last year, also removed from the market a drug it approved in 1997.  News reports are already speculating that these actions will cause the pharmaceutical industry to avoid the field, stifling research on obesity medications for years to come.

More than a third of US adults are obese, and vulnerable to obesity's damaging consequences. Obesity is responsible for the deaths of more than 100,000 Americans each year.  Costs attributable to obesity and overweight have been estimated at $270 billion annually, including direct medical costs and indirect costs, such as absenteeism and productivity losses.

"In the face of such a devastating, widespread and expensive public health crisis as obesity, it is baffling that the FDA has consistently denied approval for anti-obesity medications," said Dr. Jennifer Lovejoy, President of The Obesity Society (TOS).  "The FDA seems to expect that any obesity medication must be as free of side effects as tap water.  This is an unrealistic standard and one to which medications for other diseases are not held.  TOS will be working with several other professional societies in the coming weeks to meet with FDA and Congressional leaders and discuss improvements to the process of reviewing obesity medications."

About TOSThe Obesity Society is the leading scientific society dedicated to the study of obesity. Since 1982, The Obesity Society has been committed to encouraging research on the causes and treatment of obesity, and to keeping the medical community and public informed of new advances.Jane Prattjpratt@obesity.orgDirector of Marketing & Communications301-563-6526
'/>"/>

SOURCE The Obesity Society
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
2. Obesity Organizations Call for a Full and Fair Hearing When the FDA Reviews New Treatments for Obesity
3. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
4. InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
5. HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
6. Obesity and Diabetes Are Increasing in Cats
7. American Council on Exercise (ACE) Announces Nationwide Effort to Eliminate Obesity in America
8. Results of Two New Clinical Studies Show Promise of Emerging Mobile Health Technology to Combat Obesity Epidemic
9. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
10. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
11. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 2016 MedDay, a biotechnology company focused ... oral presentation entitled "High doses of biotin in progressive multiple ... given by Professor Ayman Tourbah , Principal Investigator of ... European Academy of Neurology (EAN) in Copenhagen, Denmark ... will take place on Sunday, 29 May 2016 from 14:45 ...
(Date:5/24/2016)... 2016 Cirujanos holandeses han puesto ... los médicos a compartir sus mejores prácticas por el ... Profesionales médicos de Europa, África, Asia ... la aplicación, que combina la transmisión en vivo con ... Educación   "Imagine un médico de ...
(Date:5/24/2016)... New Zealand , May 24, 2016 ... and informatics solutions for the healthcare sector, has been named ... New Zealand Hi-Tech Awards 2016. Dr Bruce ... fantastic acknowledgement for our team.  It,s really good to be ... burden healthcare internationally. Our products are used in 35 countries ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... Retinal Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June 4, ... the public. , Dr. Maisel, founder of Retina Group of New York ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... of comprehensive treatment for eating disorders, is opening a brand new child and ... individuals ages 8-17 and their families with even more specialized eating disorder treatment ...
(Date:5/26/2016)... ... ... The MIAMI Institute for Age Management and Intervention celebrates Global Wellness Day with ... Adonis , Wellness Physician of the MIAMI Institute is certified by the American Academy ... , He also heads up FITTLab, the comprehensive medical testing lab located in The ...
(Date:5/26/2016)... Grants Pass, OR (PRWEB) , ... May 26, 2016 , ... ... founder of Bio-Logic Aqua® Research Water Life Science® and international water advocate, was honored ... descendant of the women in ancient Egypt who knelt on the banks of the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Saint Francis ... several years, and the efforts have paid off. Since implementation of these ... of care to enhance perioperative patient experiences and reduce costly complications. Since implementation ...
Breaking Medicine News(10 mins):